Literature DB >> 2477137

Clinical and radiologic assessments of the results of hepatectomy for small hepatocellular carcinoma and therapeutic arterial embolization for postoperative recurrence.

K Takayasu1, Y Muramatsu, N Moriyama, H Hasegawa, M Makuuchi, N Okazaki, S Hirohashi, S Tsugane.   

Abstract

To study the prognostic significance of the state of the residual liver after hepatectomy for small hepatocellular carcinoma (s-HCC) no larger than 5 cm in diameter, 123 patients were followed for periods from 9 months to 9 years and 1 month. The following results were obtained: (1) recurrence occurred in the residual liver in 58 patients (54.2%) after an average of 14.9 months from hepatectomy; (2) at recurrence diagnosed by imaging, 12 of 48 recurrent patients showed negative alpha-fetoprotein; (3) computed tomography (CT) had a high sensitivity (71.4%) in detecting recurrence; (4) 5-year survivals for all patients (n = 123) who had hepatectomy, and for those without recurrence (n = 49) or with recurrence (n = 58) were 19.1%, 48.9%, and 11.0%, respectively; and (5) survivals for the patients who developed recurrence and who did and did not receive embolization treatment (n = 32, 23, respectively) were 70.3% and 37.1% at 1 year, 45.0% and 0% at 3 years, and 14.9% and 0% at 5 years, respectively. It is important to recognize that the patient who has undergone surgery even for s-HCC should be followed as a super high-risk patient at regular intervals using CT. Therapeutic embolization for recurrent patients improved the survival after recurrence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477137     DOI: 10.1002/1097-0142(19891101)64:9<1848::aid-cncr2820640916>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Hepatocellular carcinoma.

Authors:  T Ezaki
Journal:  BMJ       Date:  1992-01-25

2.  MEK1 expression and its relationship with clinical pathological features in hepatocellular carcinoma.

Authors:  Renhua Gong; Dengqun Sun; Xingguo Zhong; Yanjun Sun; Li Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.

Authors:  Hiroyuki Kishimoto; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

4.  Operative results in 143 patients with hepatocellular carcinoma.

Authors:  T Segawa; R Tsuchiya; J Furui; K Izawa; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

5.  Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization.

Authors:  K S Jeng; F S Yang; H J Chiang; I Ohta
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

Review 6.  [Liver resections for primary liver malignancies. Personal results and analysis of the literature].

Authors:  J Zieren; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir       Date:  1994

Review 7.  Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.

Authors:  Peter Gunvén
Journal:  Med Oncol       Date:  2007-08-03       Impact factor: 3.064

8.  CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours.

Authors:  T J Vogl; K Engelmann; M G Mack; R Straub; S Zangos; K Eichler; K Hochmuth; E Orenberg
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

9.  Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care.

Authors:  Weng Ng; Susannah Jacob; Geoff Delaney; Viet Do; Michael Barton
Journal:  Gastroenterol Res Pract       Date:  2015-03-26       Impact factor: 2.260

10.  Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria.

Authors:  Zhenhua Hu; Jie Zhou; Zhiwei Li; Jie Xiang; Ze Qian; Jian Wu; Min Zhang; Shusen Zheng
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.